Abstract
The observed airways inflammation in asthma and chronic cough supports the conclusions of clinical trials, namely, that our treatment regimens should emphasize inhaled cromolyn. The need for bronchodilators as backup therapy is real but represents testimony to the fact that in some cases it has not been possible to entirely eliminate the inflammation and the consequent airways hyperresponsiveness.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
